Amgen, Inc. vs Global X Defense Tech ETF — how do they compare? Amgen, Inc. trades at $412.15 (market cap $224.14B), while Global X Defense Tech ETF trades at $69.67. The key difference: Amgen, Inc. pays a 2.43% dividend while Global X Defense Tech ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | SHLD | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $417.20 | $78.02 |
52-Week Low | $271.18 | $58.20 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →